SHSiva Hemalatha

Siva Hemalatha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Siva Hemalatha has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Satyendra K. Prasad

    Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, India

    9 shared publications
  • Kancharla Bhanukiran

    Department of Pharmacognosy GITAM School of Pharmacy GITAM (Deemed to be University) Visakhapatnam Andhra Pradesh INDIA

    8 shared publications
  • Alakh Niranjan Sahu

    Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi, 221005, Uttar Pradesh, India

    6 shared publications
  • Apurva Joshi

    Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    6 shared publications
  • Damiki Laloo

    Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi, India; Girijananda Chowdhury Institute of Pharmaceutical Sciences, Guwahati, Assam, India

    5 shared publications
  • Dk Patel

    Pharmacognosy Research Laboratory, Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi-221005, India

    5 shared publications

Latest Publications

  • Untargeted identification and targeted quantification of the marker compound in Gmelina asiatica L. using UHPLC-Q Exactive Orbitrap MS and validated UHPLC-TQ-MS/MS methods

    by Rasha Ksirri, Siva Hemalatha

    Untargeted UHPLC-Q Exactive Orbitrap MS supported marker compound selection, while targeted UHPLC-TQ-MS/MS confirmed and quantified verbascoside in Gmelina asiatica .

  • Public Drug Procurement and Distribution in India: A Performance Assessment Study Across Seven different states from Diverse Geographic Regions

    by Manikandan Arumugam, Vinay Kumar Gupta, Hemalatha Siva

    Introduction: India faces significant challenges in providing access to basic healthcare and necessary medications to its large population, despite the remarkable expansion of the country's pharmaceutical sector. About 20 percent of drugs that are procured fail in the quality control tests, impacting public confidence. With a focus on the need for multifaceted assessments to improve drug availability, quality, and public confidence, this study aims to evaluate the efficiency, effectiveness, and quality of public drug procurement systems across seven states in India by developing a specific set of performance indicators. Methodology: Using 22 predetermined parameters that focus on efficiency, cost-effectiveness, and quality, a quantitative study was undertaken to evaluate the performance of public drug procurement systems in seven sample states during the year 2021-2022. Data was collected using a data collection tool, telephone interviews, and references to the respective medical corporation's website. The whole data collection process and the scoring framework were validated by performing a pilot study on two of the study sample states to ensure robustness across diverse regional states. Findings: The study revealed considerable differences in efficiency, cost-effectiveness, and drug quality-related performance parameters. Among the sample states, Tamil Nadu and Kerala exhibited superior drug procurement performance. Conversely, states like Odisha and Chhattisgarh faced challenges in budget allocation and compliance, underscoring the need for policy reforms. This study also highlights the need to consider geographical and financial factors for a comprehensive evaluation and enhancement of public drug procurement efficiency throughout India. Conclusion: This study examines the strengths and weaknesses of public drug procurement processes in seven states. The study also underscores the necessity for policy reforms and collaborative initiatives among various stakeholders to improve procurement processes. By implementing comprehensive evaluation methodologies and adhering to a benchmark model, policymakers can reduce substandard medications and improve public health outcomes.

  • Open Access

    In silico Exploration of Gmelina asiatica for Multitarget Neuroprotection in Alzheimer's Disease

    by Komal Rajesh Andarghiske, Kancharla Bhanukiran, Rasha Ksirri, Siva Hemalatha

    Background: Gmelina asiatica, commonly known as Asian Bushbeach, has traditionally been used for neurological disorders. Objectives: To identify the phytoconstituents activity in Alzheimer's disease through in silico approach. Materials and Methods: The following targets AChE, BACE1, GSK-3, and TACE1 were selected based on AD pathophysiology for in silico studies. The listed phytoconstituents were docked and MD simulations were carried out using Auto Dock and Desmond-maestro, respectively. Further, DFT studies were performed using Gaussview software. Results: Among all listed ligands, isorhoifolin was identified as the most effective compound based on binding scores of AChE (-10.9 kcal/mol), BACE1 (-10.2 kcal/mol), GSK-3 (-9.7 kcal/mol), and TACE1 (-9 kcal/mol). Further, molecular dynamics simulations of BACE1-isorhoifolin and AChE-isorhoifolin complexes demonstrated stability for up to 200 ns. Density Functional Theory (DFT) studies indicated isorhoifolin have energy gap of-0.162 eV along with that electrostatic potential surface map indicates its good reactivity and charge distribution. Additionally, ADMET analysis confirmed that isorhoifolin have drug-likeness properties and safe for human biological system. Conclusion: These study findings suggest that isorhoifolin from Gmelina asiatica may have potential anti-Alzheimer's activity meriting further biological evaluations.


  • Financial burdens of Pregnancy: Understanding Socioeconomic, Demographic correlates and Out-of-pocket costs

    by Manikandan Arumugam, Km Noorulla, Mohd Yasir, Manish Kalwaniya, Hemalatha Siva

    Introduction: In India, the financial burdens of pregnancy are closely tied to socioeconomic, and demographic factors, healthcare policies, and out-of-pocket costs. Health expenditure in India is around 3.2% of GDP, with public health spending making up less than half of the total expenditure. Several socioeconomic, and demographic factors significantly impact the financial burdens of pregnancy, particularly for women in vulnerable groups. Income, education, and geographical location strongly influence these costs. This study aims to investigate the socioeconomic, and demographic determinants of out-of-pocket expenditures (OOPE) during pregnancy and childbirth in the Agra district, Uttar Pradesh, India. Methods: The study utilized a cross-sectional mixed-methods design and collected data from participants through surveys and semi-structured interviews, involving different delivery locations among a diverse group of women who have given birth. The analysis focused on participants' socioeconomic, and demographic characteristics, direct and indirect expenditures, with contributing factors for OOPE and suggestions for reducing OOPE. Results: The study revealed impactful correlations between socioeconomic, and demographic factors and out-of-pocket costs during pregnancy, highlighting varying healthcare utilization patterns across delivery settings. Participants from diverse backgrounds experienced financial burdens in maternity-related care, with home deliveries showing minimal expenses but poorer healthcare access. Key factors contributing to impaired service utilization and strategies for reducing financial burdens were identified, underscoring the importance of targeted policies to enhance maternal healthcare access and affordability. Conclusion: The study's comprehensive analysis of socioeconomic, and demographic factors and out-of-pocket costs during pregnancy and childbirth provides crucial insights into the financial burdens faced by expectant mothers across diverse backgrounds. These findings underscore the necessity of targeted interventions to alleviate financial strain and improve maternal and child health outcomes through equitable access to essential care. Despite potential limitations like self-reporting bias and regional constraints, this research contributes significantly to understanding the financial aspects of pregnancy and underscores the need for supportive policies to alleviate the financial burden on expectant families.


  • Development of phytosterol-loaded silver nanoparticles for ameliorating haemorrhoidal complications via the AMPK pathway—a mechanistic approach

    by Tarkeshwar Dubey, Kancharla Bhanukiran, Siva Hemalatha

    The aim of the current study was to synthesize silver nanoparticles (PLSNPs) using green technology by means of phytosterol-enriched fractions from Blumea lacera extracts (EAF) and evaluate their toxicological and anti-haemorrhoidal potential. The average size of the synthesized particles was found to be 85.64 nm by scanning electron microscopy and transmission electron microscopy. Energy dispersive spectroscopy showed the elemental composition of PLSNPs to be 12.59% carbon and 87.41% silver, indicating the capping of phytochemicals on the PLSNPs. The PLSNPs were also standardized for total phytosterol content using chemical methods and high-perfromance liquid chromatography. The PLSNPs were found to be safe up to 1000 mg kg−1 as no toxicity was observed in the acute and sub-acute toxicity studies performed as per OECD guidelines. After the induction of haemorrhoids, experimental animals were treated with different doses of EAF, PLSNPs and a standard drug (Pilex) for 7 d, and on the eighth day the ameliorative potential was assessed by evaluating the haemorrhoidal (inflammatory severity index, recto-anal coefficient) and biochemical (tumour necrosis factor-alpha and interleukin-6) parameters and histology of the recto-anal tissue. The results showed that treatment with PLSNPs and Pilex significantly (p < 0.05) reduced haemorrhoidal and biochemical parameters. This was further supported by restoration of altered antioxidant status. Further, a marked reduction in the inflammatory zones along with minimal dilated blood vessels was observed in the histopathological study. The results of molecular docking studies also confirmed the amelioration of haemorrhoids via AMP-activated protein kinase (AMPK)-mediated reduction of inflammation and endothelin B receptor modification by PLSNPs. In conclusion, PLSNPs could be a good alternative for the management of haemorrhoids.


  • Pyrus pashia fruit extract and its major phytometabolite chrysin prevent hippocampal apoptosis and memory impairment in PTZ-kindled mice

    by Priyanka Sharma, Amita Kumari, Padmanabh Singh, Sweta Srivas, Mahendra K. Thakur, Siva Hemalatha

    Objectives: Epilepsy is a chronic neurological condition with recurrent seizures. One-third of epilepsy patients experience unacceptable side effects from antiepileptic drugs. Pyrus pashia is a deciduous tree from southern Asia. Ethnomedicinally, Malakand tribes use its fruits for epilepsy treatment. Our prior research demonstrated the anticonvulsive properties of ethanolic extract of Pyrus pashia (EPP) and its bioactive compound chrysin in acute seizure tests. This study aims to investigate the impact of EPP and chrysin on cognitive impairment in a PTZ-induced kindling mice model of epilepsy.Methods: Swiss albino male mice were equally divided into four groups. The first group received 0.5% carboxy methyl cellulose dissolved in normal saline while the other three groups were pre-treated with Diazepam (DZP) (1 mg/kg, i.p.), EPP (200 mg/kg, p.o.) and chrysin (5 mg/kg, p.o.). After 30 min, all groups were administered PTZ (35 mg/kg, i.p.) and evaluated for seizure severity, cognitive function, and neuronal apoptosis. Western blot analysis was conducted to analyze the expressions of apoptosis biomarkers and memory-related genes, including cAMP response element-binding protein (CREB) and Brain Derived Neurotrophic Factor (BDNF).Results: The therapeutic effects of EPP and Chrysin were comparable to DZP in terms of reducing seizure severity, but unlike DZP, they prevented PTZ-induced memory impairment in experimental animals. Additionally, they increased the levels of BDNF and CREB while reducing apoptotic biomarkers in the hippocampus of experimental animals.Conclusions:Based on the leads offered by this study EPP and its major bioactive constituent, could be developed as the treatment option for epilepsy.


  • Open Access

    Neuroprotective upshot of isorhoifolin flavonoid of Gmelina asiatica for multitargeted approach in Alzheimer's disease: Exploration through in-silico studies

    by Komal Rajesh Andarghiske, Bhanukiran Kancharla, Hemalatha Siva

    Alzheimer's is a progressive neurodegenerative disease with amyloid-beta peptide deposition that impairs memory and cognitive decline. In previous reports, the plant Gmelina asiatica was reported to have anti-Alzheimer’s disease (AD) activity. However, the responsible chemical constituents of G. asiatica for anti-Alzheimer’s activity have not been explored. Therefore, the present study aimed to investigate hit compounds through an in silico approach. The reported phytoconstituents were initially screened through auto dock software. Then, the lead compound was further evaluated through molecular dynamic studies. Further hit compound isorhoifolin physicochemical and ADMET properties were analyzed. In docking studies, isorhoifolin showed the least binding energy and well resided at the active sites of AchE (-10.9 kcal/mol), BACE1 (-10.2 kcal/mol), GSK-3 (-9.7 kcal/mol), TACE1 (-9 kcal/mol). Further molecular dynamic simulation revealed that isorhoifolin is stable up to 200 ns. Furthermore, density functional theory (DFT) was analyzed using Gaussian software, where the quantum mechanics objective was focused. Besides, the physicochemical properties of isorhoifolin were studied, such as absorption, distribution, metabolism, excretion, and toxicity, through the pkcsm software. The study suggests isorhoifolin from the Gmelina asiatica plant may be responsible for anti-Alzheimer's activity, which may be considered for further investigation.

  • Evaluation of anticancer activity of Gmelina asiatica leaves, in-vitro and in-silico studies

    by Rasha Ksirri, Kancharla Bhanukiran, Swapan Maity, Pralay Maiti, Siva Hemalatha

    Cervical cancer poses a major threat to women's health worldwide, constituting the fourth most prevalent cancer among the female population. High-risk variants of human papillomavirus (HPV) with its oncogenic proteins are a necessary cause of cervical cancer. Due to the resistance of cancer cells to the current treatment, there is a need for new medicines with new strategies to treat cervical cancer. Gmelina asiatica Linn. is a medicinal plant with various traditional uses and biological activities. Its anticancer potential against breast cancer and lymphoma has been demonstrated in the literature. In view of this, our study aims to investigate the anticancer activity of Gmelina asiatica leaves against cervical cancer. Various extracts of Gmelina asiatica leaves were prepared by soxhletation and maceration methods. The cytotoxic activity of the extracts was evaluated through in-vitro studies against SiHa cell line using MTT assay and fluorescence imaging. The most potent extract (GAME) phytochemical profile was analysed by UHPLC-HRMS. Further, in-silico studies were performed on its phytoconstituents against E6 oncoprotein, and the DFT studies were conducted on the active component to assess the physicochemical properties. In-vitro studies revealed that methanolic extract (GAME) showed the highest inhibition on the SiHa cell line compared to the other extracts and the control (p < 0.0001). In-silico studies indicated high affinity with stable interaction of the compound 5 (JC5ABDR) at E6 binding sites. This study revealed the importance of Gmelina asiatica plant as a potential source of anticancer molecules with a specific mode of action against cervical cancer.Communicated by Ramaswamy H. Sarma